Abstract: The invention is directed to a method for treating an inflammatory disorder of the lower airways in a human subject in need thereof, comprising administering an effective amount of a recombinant human IL-1 receptor antagonist (rhIL-IRa) directly to the lower airways in the human subject; wherein the inflammatory disorder is caused by a coronavirus infection.

Abstract: A method for treating an inflammatory disorder of the lower airways in a human subject in need thereof is described, including administering an effective amount of anakinra directly to the lower airways in the human subject; where the effective amount of anakinra is from about 0.1 mg to about 200 mg per day; and where the inflammatory disorder is selected from the group consisting of a toxic-inhalation lung injury, pulmonary langerhans cell histiocytosis, non-cystic fibrosis bronchiectasis, diffuse panbronchiolitis, acute respiratory distress syndrome (ARDS), reactive airways dysfunction syndrome (RADS), bronchiolitis obliterans organizing pneumonia and pneumonitis.